Orexin System Suppression is the targeted pharmacological or physiological reduction of activity in the orexinergic (also known as hypocretinergic) system, a neuropeptide network originating in the hypothalamus that is crucial for promoting wakefulness and regulating appetite. Clinically, suppression is employed to facilitate the transition into and maintenance of sleep by dampening the potent wake-promoting signal. This intervention highlights the critical neuroendocrine control of the sleep-wake cycle.
Origin
The orexin system was discovered in the late 1990s, and its critical role in narcolepsy and wakefulness quickly established it as a major target for sleep-disorder therapeutics. The term “suppression” is a direct reference to the mechanism of action of dual orexin receptor antagonists (DORAs), a class of hypnotics.
Mechanism
The orexin peptides, Orexin A and Orexin B, bind to their cognate receptors (OX1R and OX2R) on various nuclei throughout the brainstem and forebrain, stimulating excitatory neurotransmission and stabilizing the awake state. Suppression operates by blocking these receptors, thereby preventing the orexin signal from activating downstream wake-promoting monoaminergic and cholinergic neurons. This pharmacological intervention allows the endogenous sleep-promoting drive to prevail, facilitating sleep onset and continuity.
We use cookies to personalize content and marketing, and to analyze our traffic. This helps us maintain the quality of our free resources. manage your preferences below.
Detailed Cookie Preferences
This helps support our free resources through personalized marketing efforts and promotions.
Analytics cookies help us understand how visitors interact with our website, improving user experience and website performance.
Personalization cookies enable us to customize the content and features of our site based on your interactions, offering a more tailored experience.